Erratum: Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy (European Journal of Clinical Microbiology and Infectious Diseases DOI 10.1007/s10096-008-0612-5);Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 28, Issue 3, 2009, Pages 297-300

  Valentini, P ^a   Annunziata, M L ^a   Angelone, D F ^a   Masini, L ^a   De Santis, M ^a   Testa, A ^a   Grillo, R L ^a   Speziale, D ^a   Ranno, O ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DIHYDROFOLATE REDUCTASE; FOLINIC ACID; PYRIMETHAMINE; SPIRAMYCIN; SULFADIAZINE;

ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MOTHER CHILD RELATION; NEWBORN; PREGNANCY; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 61349097868     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-009-0756-y     Document Type: Erratum

References (12)

1. G Desmonts J Couvreur 1974 Toxoplasmosis in pregnancy and its transmission to the fetus Bull N Y Acad Med 50 146 159
2. SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group 2007 Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data Lancet 369 115 122
3. Masini L, De Santis M, Noia G et al (2003) Maternal therapy in prevention of congenital toxoplasmosis. In: Program and abstracts of the International Conference on Toxoplasmosis-Biology, Clinical Practice and Public Health, Copenhagen, Denmark, June 2003, abstract no. 25
4. F Derouin E Jacqz-Aigrain P Thulliez J Couvreur C Leport 2000 Cotrimoxazole for prenatal treatment of congenital toxoplasmosis? Parasitol Today 16 254 256
5. O Ranno W Buffolano P Della Casa M Mombrò M Stronati 1998 Guidelines for congenital toxoplasmosis diagnosis Pediatr Neonatal Rev 1 2 8
6. E Nucera D Schiavino A Buonomo M Del Ninno JY Sun G Patriarca 2000 Tolerance induction to cotrimoxazole Allergy 55 7 681 682
7. BT Nguyen S Stadtsbaeder 1985 Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole) and spiramycin in pregnant mice infected with Toxoplasma gondii (Beverley strain) Br J Pharmacol 85 713 716
8. J Arens K Barnes N Crowley G Maartens 2007 Treating AIDS-associated cerebral toxoplasmosis-pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids S Afr Med J 97 956 958
9. T Yang MC Walker D Krewski Q Yang P Garner W Fraser 2007 Occurrence and determinants of trimethoprim/sulfamethoxazole use in pregnancy Acta Obstet Gynecol Scand 86 1310 1316
10. AE Czeizel M Rockenbauer HT Sørensen J Olsen 2001 The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study Reprod Toxicol 15 637 646
11. F Forna M McConnell FN Kitabire J Homsy JT Brooks J Mermin 2006 Systematic review of the safety of trimethoprim-sulfamethoxazole for prophylaxis in HIV-infected pregnant women: implications for resource-limited settings AIDS Rev 8 24 36
12. R McLeod K Boyer T Karrison K Kasza C Swisher N Roizen 2006 Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study Clin Infect Dis 42 1383 1394